Patent · US Active

Selective androgen receptor degrader (SARD) ligands and methods of use thereof

US9834507B2 · kind B2 · utility

11Cited by

14References

41Claims

0Family size

Assignees

University of Tennessee Research Foundation · US
GTX Corp · US

Inventors

Ramesh Narayanan · Cordova, US
Duane D. Miller · Germantown, US
Thamarai Ponnusamy · Memphis, US
Dong-Jin Hwang · Arlington, US
Charles B. Duke · Memphis, US
Christopher C. Coss · Upper Arlington, US
Amanda Jones · Gaylord, US
James T. Dalton · Columbus, US

Key dates

Filing date	Oct 21, 2016
Grant date	Dec 5, 2017
Priority date	—
Expiry date	Oct 21, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/07
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.